drugset / Trial / NCT03399903
Study of Pentasa® for Reducing Residual Systemic Immune Activation in Treated HIV Infection
Phase 1/2
Completed
47 enrolled
AIDS Healthcare Foundation
HIV Immunotherapeutics Institute · collab
RandomizedParallel-groupOpen-labelPrevention
Summary
An open label study will be performed on 80 people with HIV infection who are maintained on effective treatment with antiretroviral drugs.
Timeline
- Start
- 2017-05-01
- Primary completion
- 2019-03-22
- Completion
- 2019-03-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Mesalamine | Small molecule | 1 g | Oral |
| Subject | VSL#3 | Other / unclassified | — | Oral |